# Pemetrexed Disodium and Cisplatin in Treating Patients Who Are Undergoing Surgery for Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer

> **NCT00248495** · PHASE2 · COMPLETED · sponsor: **Roswell Park Cancer Institute** · enrollment: 38 (actual)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** cisplatin
- **DRUG:** pemetrexed disodium
- **PROCEDURE:** adjuvant therapy
- **PROCEDURE:** conventional surgery
- **PROCEDURE:** neoadjuvant therapy

## Key facts

- **NCT ID:** NCT00248495
- **Lead sponsor:** Roswell Park Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-06-08
- **Primary completion:** 2011-04-29
- **Final completion:** 2017-04-05
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2017-07-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00248495

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00248495, "Pemetrexed Disodium and Cisplatin in Treating Patients Who Are Undergoing Surgery for Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00248495. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*